nach oben

Erschienen in:

01.06.2019 | Case report

Ribavirin

Various toxicities secondary to off-label use: 8 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a case report, two men and six women aged 30−43 years from India were described, who developed elevated levels of bilirubin, fever, nausea, decreased haemoglobin, fatigue, dizziness, anorexia, palpitations, exertional dyspnoea, headache, malaise, dysgeusia or dry mouth during off label prophylactic treatment with ribavirin following exposure to Nipah virus infected patients. …

Banerjee S, et al. First experience of ribavirin postexposure prophylaxis for Nipah virus, tried during the 2018 outbreak in Kerala, India. Journal of Infection 78: 491-503, No. 6, Jun 2019. Available from: URL: http://doi.org/10.1016/j.jinf.2019.03.005 - IndiaCrossRefPubMed

Titel: Ribavirin
Various toxicities secondary to off-label use: 8 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-64119-1

Springer Medizin

Ribavirin

Various toxicities secondary to off-label use: 8 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Pembrolizumab

Warfarin

Influenza virus vaccine

Bendamustine/brentuximab-vedotin

Hydroxycarbamide

Tenofovir disoproxil fumarate

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Pembrolizumab

Warfarin

Influenza virus vaccine

Bendamustine/brentuximab-vedotin

Hydroxycarbamide

Tenofovir disoproxil fumarate